Radiotherapy

Stereotactic body radiation therapy for localized prostate cancer is associated with high 12-year rates of biochemical disease-free survival.

Fluciclovine PET/CT plus conventional imaging vs conventional imaging alone to guide radiation therapy for men with recurrent PCa following radical prostatectomy results in improved failure-free survival, according to the first randomized trial comparing the 2 approaches.

Black race is associated with improved oncologic outcomes among men undergoing radiation-based therapy for high-risk prostate cancer, new findings suggest.

Pretreatment counts of 5 CTCs per 7.5 mL of blood or higher correlated with shorter survival compared with lower counts among men with metastatic castration-resistant prostate cancer treated with radium-223, a study found.

Radiation therapy for higher-risk prostate cancer can be delayed for up to 6 months following initiation of hormonal therapy without incurring a greater mortality risk, a finding that has implications for patient care during the COVID-19 pandemic.

Allowing an approximately 24-month recovery period after prostate surgery before giving radiation therapy may be optimal for preserving erectile function provided oncologic control is not compromised, according to investigators.